The Israeli-based company, Medasense, has developed a unique platform, PMD-200, that objectively monitors and quantifies a patient's pain response through artificial intelligence and a proprietary non-invasive sensor platform. This platform is used to optimize pain management in operating rooms and critical care settings, where patients are unable to communicate. The company's pipeline includes cloud-based solutions for clinics and home, leveraging the NOL technology, which addresses an additional $15B global market. The PMD-200 is distributed in Europe exclusively by Medtronic and cleared for marketing in Canada, Latin America, and Australia, and enables connectivity with Philips patient monitors. Clinical studies have demonstrated its impact on patient safety and outcomes, including opioid-sparing. Medasense is also developing NOLedge, an investigational device to lead prediction, stratification, and prevention strategies that will enable better pain management and reduce healthcare expenditures.